Supplementary material

Early Sacubitril/Valsartan-driven Benefit on Exercise Capacity in Heart Failure With Reduced Ejection Fraction: A Pilot Study

SUPPLEMENTARY MATERIAL

Figure 1 of the supplementary material. Flowchart for patient inclusion and follow-up. ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; CPET, cardiopulmonary exercise testing; HF, heart failure; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association functional class.
Figure 2 of the supplementary material. Thirty-day effects of sacubitril/valsartan on quality of life, NT-proBNP and renal function. A: changes of MLHF. B: changes of log of NT-proBNP. C: changes of estimated glomerular filtration rate. eGFR, estimated glomerular filtration rate using the Modification of Diet in Renal Disease formula; MLHF, Minnesota Living with Heart Failure Questionnaire; NT-proBNP, N-terminal pro-B-type natriuretic peptide. Adjusted for baseline values of the exposures.